threat brolucizumab wamd
proprietari survey indic brolu like see robust launch shift
share exist anti-vegf particularli among tx-experienc pt conserv
incorpor doc est brolu uptak cut eylea rev wamd next
yr revis eylea est fall con think st
underestim impact brolu entri could replic event seen eylea
launch encroach lucenti share
cut eylea number wamd bullish outlook brolucizumab
doc survey view novarti brolucizumab brolu favor w/ retina specialist
particularli eager prescrib importantli ioi rate piii hawk trial
rais concern view compar eylea/lucenti eylea share
appear risk tx-experienc pt doc est suggest brolu could achiev
share convers kol angiogenesi mtg
point toward wareh elig pt brolu remain uncontrol anti-
vegf residu fluid kol estim pt fit descript
align w/ survey find could contribut bolu rx gate
conserv discount eylea share shift wamd still model y/i revenu
impact translat loss
outer year revis market model drive
new pt prev
lucenti play unlik move needl across retin diseas
biosimilar threat lucenti could materi earli survey
suggest impact mute wamd dme pdr/npdr estim uptak
rang undiscount across retin diseas w/ doc lukewarm
willing prescrib major plan write rx wamd dme
requir payer anoth doc state intent activ push back
payer-mand biosimilar substitut roch next gen lucenti pd vast
major doc plan adopt wait-and-se strategi w/ concern around surgic
implant rate endophthalm highlight barrier adopt
limit inroad eylea npdr unlik counteract brolucizumab impact
survey impli minim uptak eylea pdr npdr back posit
piii panorama data wk per doc est eylea could see undiscount
share gain pdr/npdr quickli erod lucenti biosimilar reach
market high avastin usag non-drug therapi option simpli treat
case npdr continu domin market indic
anticip approv eylea npdr may pdufa unlik meaning drive
rx increas pressur franchis expect beyond
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
expect sale ex-u profit share
eylea
expect ww profit share praluent
expect ww profit share dupix
expect ww profit share kevzara
expect profit share ex-u profit share
libtayo
stabl eylea share market entri anti-vegf competitor
approv dupix follow-on indic includ nasal
approv kevzara follow-on indic includ non-
praluent see better market access reduc net price
declin eylea share market entri anti-vegf
dupix launch atop dermat and/or asthma
under-perform and/or ex-u market
unsuccess negoti payer
libtayo launch cscc underperform and/or ex-u
includ wamd crvo dme eylea oppi
includ adult/pediatr atop dermat asthma
includ moderate-to-sever ra fail methotrex
biolog kevzara oppi
includ hypercholesterolemia hefh praluent oppi
includ cscc libtayo oppi nsclc repres
io combo libtayo bispecif antibodi program
pdufa date praluent label updat cv
pdufa date praluent first-lin treatment
pdufa date eylea diabet retinopathi
sbla file dupix chronic sinusitis/nas
initi trial pozelimab pnh
enrol updat piii trial libtayo nsclc
monotherapi yervoy combo
base pro forma financi statement
pleas see import disclosur inform page report
financi summari market data
estim valuat
pleas see import disclosur inform page report
tabl content
 brolucizumab launch expect largest headwind face
eylea fy
 eylea chang
retina specialist appear eager prescrib brolucizumab
 lucenti biosimilar pd like initi mover
 lacklust expect eylea uptak npdr despit
pleas see import disclosur inform page report
conduct proprietari survey current futur treatment landscap
back eye diseas includ wet age-rel macular degener wamd
diabet macular edema dme proliferative/non-prolif diabet retinopathi
pdr/npdr goal survey assess potenti uptak sever near-to-
biosimilar sever manufactur lucenti port deliveri system pd roch
sw buy welford repres competit threat establish eylea franchis
buy across retin diseas also sought evalu impact
recent posit piii panorama data pdufa date may drive potenti
uptak eylea pdr/npdr on-line survey complet board-certifi
spectrum practic set treat averag wamd dme pdr
npdr patient per month center
brolucizumab launch expect largest headwind
face eylea fy
recal bla file brolucizumab brolu accept fda april
novarti use prioriti review voucher expedit review product target
launch ye present piii hawk harrier data respond
ask estim expect prescrib brolu treatment-na treatment-
experienc wamd patient averag wamd patient classifi
doc treatment-na wherea treatment-experienc previous
share ye ye roughli equival share shift come
eylea lucenti glass vial pre-fil syring combin avastin
share ye ye eylea disproportion bore brunt
share shift ye compar anti-vegf therapi eylea lucenti
glass vial pre-fil syring combin avastin exhibit
exhibit anti-vegf treatment statu wamd patient
pleas see import disclosur inform page report
exhibit current project market share treatment-na wamd
exhibit current project market share treatment-experienc wamd
pleas see import disclosur inform page report
eylea chang model
translat share shift driven brolu treatment-na -experienc wamd
potenti revenu impact eylea first discount prescrib estim brolu
level haircut consist appli across doc survey address
physician enthusiasm new product typic overestim usag first
year launch pool estim eylea share shift treatment-na
treatment-experienc patient current level ye current level
ye ye discount share shift given brolu launch
expect get underway earli like repres
full year sale ye discount share shift full
impact brolu eylea share begin recogn second year launch
exhibit note math impli eylea share wamd cut current
level ye cut ye therefor total
current level ye
exhibit estim eylea share shift wamd
directli appli discount eylea share shift estim fy revenu
number eylea wamd reduc fy revenu estim y/i arriv
reduc fy estim y/i arriv near-term
estim outer year also reduc result reset run rate lower
revenu fy previous model continu sale growth eylea y/i
year arriv fy fy believ
ignor underestim impact brolu launch model chang reduc wamd
revenu fy fy annual thereaft
exhibit term total eylea revenu note current model sale wamd
central retin vein occlus crvo dme ex-u market
market model wamd consid eylea share exclus patient treat avastin
 market share among anti-vegf agent back avastin-tr patient
follow implement chang discuss updat wamd model
fy depict exhibit
exhibit updat eylea revenu wamd
pleas see import disclosur inform page report
treatmentcurr ye ye treatment-nav treatment-experienc wamdu eylea revenu wamdfi chang chang exhibit updat wamd market model
incorpor brolu launch model previou total eylea revenu
estim reduc consensu fy fall
street expect time-frame accordingli previou non-gaap ep
estim fy alreadi lower consensu reduc
fall consensu period exhibit
exhibit updat total eylea revenu non-gaap ep estim
retina specialist appear eager prescrib
brolucizumab favor efficacy/safeti profil
base piii hawk harrier data week respond bullish
brolu profil efficaci safeti perspect consid efficaci data
alon retina specialist report higher willing prescrib scale
repres highest willing compar non-retina specialist
first year product launch howev retina specialist
non-retina specialist demonstr notabl increas willing
prescrib efficaci second year launch exhibit also gave respond
option provid unsolicit comment efficaci data major
doc opt give feedback tone comment lean posit
neg neutral doc mention potenti greater durabl retin
pleas see import disclosur inform page report
wet patient patient diagnos wet patient diagnos wet pt receiv treatment total patient receiv avastin treat patient receiv anti-vegf patient receiv eylea eylea-tr pt entir sale wet price/inject annual annual estimatesprevi estimatesconsensu estimatesprevi estimatesconsensu non-gaap total eylea revenu equiti research
fluid improv key strength profil reason prescrib doc
chose focu compar superior efficaci eylea detriment exhibit
exhibit brolucizumab willing prescrib efficaci
exhibit respond view brolucizumab efficaci
recal meet novarti present two-year hawk harrier result
brolu intraocular inflamm ioi rate observ
pleas see import disclosur inform page report
former latter slightli higher rate ioi seen hawk
discuss point investor rais doc howev current
survey found retina specialist non-retina specialist
gener will prescrib first year launch base exist
safeti data willing prescrib substanti rose second year launch
retina specialist non-retina specialist alik presum
doc grew comfort safeti real-world set exhibit comfort among
doc safeti profil reinforc voluntari comment doc gave
feedback lean posit neg neutral align
comment efficaci major respond view ioi rate accept
appreci differ compar eylea lucenti concern voic around uveiti
iriti endophthalm appear minor exhibit
exhibit brolucizumab willing prescrib safeti
pleas see import disclosur inform page report
exhibit respond view brolucizumab safeti
better understand patient like initi receiv brolu ask
respond estim percentag treatment-experienc wamd patient
continu retin fluid/uncontrol diseas eylea lucenti avastin consid
uncontrol patient ask doc estim percentag
patient would elig switch anoth anti-vegf agent brolu
three commonli use anti-vegf agent lowest percentag uncontrol patient
report eylea would consid switch
agent like brolu second best control achiev lucenti uncontrol
patient amount similar proport eylea doc would consid
uncontrol patient lucenti switch anoth anti-vegf agent lastli
avastin demonstr highest number uncontrol patient
would consid switch anoth anti-vegf agent exhibit
math suggest eylea patient lucenti patient
avastin patient view good candid brolu would first switch
pleas see import disclosur inform page report
therapi find align anecdot input doc angiogenesi
meet one kol mention wamd patient remain uncontrol
current anti-vegf therapi like receiv brolu see note
exhibit uncontrol patient anti-vegf therapi would consid
lucenti biosimilar pd like initi
mover retin diseas
biosimilar expect enter market anti-vegf class near futur
sever lucenti biosimilar develop first expect reach
 market lucenti patent expiri eu exhibit
sever eylea biosimilar also develop although product like
later market eylea patent expiri eu recal
approv biosimilar result grant indic refer
biolog approv without need multipl clinic trial therefor first lucenti
biosimilar approv could see uptak across wamd dme pdr/npdr
anticip event queri respond potenti prescrib ye
previous note indic assum launch doc lukewarm
prescrib lucenti biosimilar across retin diseas modest uptak
expect treatment naiv wamd treatment-experienc wamd treatment-
naiv dme treatment-experienc dme pdr npdr exhibit
moreov unadjust valu consid typic discount
doc estim uptak would even lower
exhibit lucenti biosimilar develop
pleas see import disclosur inform page report
biosimilarmanufacturerexpect approv eu eu bioepi south korea undetermin piii inc usa undetermin pi/ii bioscienc usa undetermin preclin fyb ag germani bioeq gmbh germani xlucanexbran biopharma sweden exhibit current project market share lucenti biosimilar retin
among respond retina specialist non-specialist somewhat will
prescrib lucenti biosimilar wamd first year market
improv second year exhibit importantli
half respond indic plan prescrib lucenti biosimilar
treatment-na treatment-experienc wamd requir health insur
plan around addit respond indic would activ challeng
biosimilar substitut mandat payer non-retina specialist notabl
reluct prescrib biosimilar treatment-na treatment-experienc
wamd suggest segment prescrib slower adopt exhibit
exhibit willing prescrib lucenti biosimilar wamd
pleas see import disclosur inform page report
currenty ye ye ye retina non-retina retina non-retina retina non-retina retina non-retina retina non-retina retina non-retina moderate-sever sever drss scale treatmentwamd treatment-navewamd treatment-experienceddm treatment-navedm treatment-experiencedpdrwilling prescrib wamdal specialist non-specialist wamd pt treatedlucenti will will will exhibit view toward payer mandat prescrib lucenti biosimilar
dme respond willing prescrib biosimilar gener mirror
wamd willing mute first year launch
improv time market second year exhibit
around half respond would prescrib treatment-na treatment-
experienc dme face requir payer indic would push
back requir non-retina specialist remain bearish prescrib
biosimilar dme compar retina specialist exhibit
exhibit willing prescrib lucenti biosimilar dme
pleas see import disclosur inform page report
view toward prescrib treatment-nav wamdal specialist non-specialist would prescrib lucenti biosimilar prior brand anti-vegf agent without requir would prescrib lucenti biosimilar prior brand anti-vegf agent requir would prescrib lucenti biosimilar prior brand anti-vegf agent plan challeng biosimilar substitut requir toward prescrib treatment-experienc wamdal specialist non-specialist would prescrib lucenti biosimilar prior brand anti-vegf agent without requir would prescrib lucenti biosimilar prior brand anti-vegf agent requir would prescrib lucenti biosimilar prior brand anti-vegf agent plan challeng biosimilar substitut requir biosimilarwilling prescrib dmeall specialist non-specialist dme pt treatedlucenti will will will exhibit view toward payer mandat prescrib lucenti biosimilar dme
gaug recept roch lucenti port deliveri system pd provid brief
overview implant process ladder data wamd recal ladder
assess treatment-experienc wamd patient demonstr median time first
refil month pd mg/ml patient pd mg/ml went
month refil given best result seen mg/ml roch select
go-forward dose piii archway studi fix interv
design conserv intend secur regulatori approv real-world practic
roch think patient could go longer week month base ladder
data concern vitreou hemorrhag earli ladder studi
roch issu instruct use ifu optim surgic techniqu greatli
reduc hemorrhag event month surgeri rate
endophthalm also note safeti databas ladder
survey willing prescrib pd averag
first year product launch retina non-retina specialist enthusiasm
product expect modestli improv second year launch yet remain
averag across group prescrib exhibit respond
offer unsolicit feedback pd reinforc gener neg lean view
comment classifi posit negative/neutr exhibit
comment highlight concern higher risk endophthalm hassl
perform minor surgic procedur offic doc note take office-
base diseas surgic diseas patient may will endur invas
procedur associ discomfort doc clearli posit pd
note advantag fewer inject potenti long-term cost save
pleas see import disclosur inform page report
